证券代码：600568 证券简称：ST 中珠 公告编号：2023-044 号 中珠医疗控股股份有限公司 关于召开 2022 年度业绩说明会的公告 特别提示 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 09 日（星期二）至 05 月 15 日（星期一）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zz600568@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）已于 2023 年 4 月 20 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 5 月 16 日（星期二）上午 10:00-11:00 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果及财 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 117,820,377.20, representing a decrease of 3.82% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 27,828,721.13, a significant decline of 577.44% year-on-year[5]. - Basic and diluted earnings per share were both CNY -0.0140, reflecting a decrease of 566.67% compared to the same period last year[6]. - Total operating revenue for Q1 2023 was ¥117,820,377.20, a decrease of 3.5% compared to ¥122,493,820.06 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥21,844,934.44, compared to a profit of ¥1,621,721.13 in Q1 2022[21]. - The total comprehensive loss for Q1 2023 was ¥21,955,975.58, compared to a comprehensive income of ¥1,622,794.27 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY 55,884,126.32, down 71.31% from the previous year[5]. - Cash flow from operating activities increased significantly to ¥153,428,109.94 in Q1 2023, compared to ¥97,155,935.90 in Q1 2022, representing a growth of 57.9%[24]. - The net cash flow from operating activities was -$55.88 million, compared to -$32.62 million in the previous year, indicating a decline in operational performance[25]. - Cash and cash equivalents were reported at RMB 515,850,737.83, a decrease from RMB 577,180,844.05, reflecting a decline of approximately 10.65%[17]. - Cash and cash equivalents at the end of the period totaled $331.13 million, down from $562.68 million at the end of the previous year[26]. - The net increase in cash and cash equivalents was -$62.80 million, contrasting with a positive increase of $35.34 million in the previous year[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,640,085,392.25, a decrease of 1.96% from the end of the previous year[6]. - The company's current assets totaled RMB 1,771,922,816.09, down from RMB 1,839,334,761.76, indicating a decrease of about 3.67%[18]. - The company's total liabilities decreased to ¥725,342,877.67 in Q1 2023 from ¥775,972,082.61 in Q1 2022, a reduction of approximately 6.5%[20]. - The company's long-term equity investments stood at RMB 349,482,036.42, a minor decrease from RMB 352,514,093.13, representing a decline of approximately 0.91%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,739[13]. - The top shareholder, Shenzhen Landi Technology Development Co., Ltd., holds 19.08% of the shares, with 380,172,862 shares pledged[13]. Expenses and Costs - The company experienced a 31.38% increase in sales expenses, attributed to higher costs in the pharmaceutical sector[11]. - Total operating costs increased to ¥136,899,729.17 in Q1 2023, up 7.4% from ¥126,995,078.54 in Q1 2022[20]. - Research and development expenses rose to ¥4,555,699.77 in Q1 2023, up from ¥3,727,371.97 in Q1 2022, indicating an increase of 22.2%[21]. - Cash paid for purchasing goods and services was $51.50 million, down from $65.75 million in the previous year, indicating cost control measures[25]. - The company paid $61.32 million in employee compensation, an increase from $51.68 million in the previous year, reflecting higher labor costs[25]. Investment and Future Outlook - The company reported an investment loss of ¥1,065,207.38 in Q1 2023, compared to a gain of ¥1,473,744.90 in Q1 2022[21]. - The company has not disclosed any new product developments or technological advancements in the provided documents[16]. - There were no significant updates regarding market expansion or mergers and acquisitions mentioned in the conference call[16]. - The company has not provided specific future guidance or performance outlook in the available reports[16].

Financial Performance - The company reported a net profit attributable to the parent company of -¥799,221,521.72 for the year 2022, with a parent company net profit of -¥296,662,674.12[6] - The undistributed profits at the beginning of the year were -¥1,501,827,304.05, and by the end of 2022, they decreased to -¥2,301,048,825.77[6] - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves for the year 2022 due to the negative profit situation[6] - The company's operating revenue for 2022 was approximately ¥505.97 million, a decrease of 12.92% compared to ¥581.06 million in 2021[27] - The net profit attributable to shareholders for 2022 was approximately -¥799.22 million, representing a significant decline of 278.27% from -¥211.28 million in 2021[27] - The net cash flow from operating activities decreased by 72.86% to approximately ¥25.52 million in 2022, down from ¥94.04 million in 2021[27] - The total assets at the end of 2022 were approximately ¥3.71 billion, a decrease of 16.72% from ¥4.46 billion at the end of 2021[27] - The net assets attributable to shareholders decreased by 22.23% to approximately ¥2.80 billion at the end of 2022, down from ¥3.60 billion at the end of 2021[27] - The basic earnings per share for 2022 was -¥0.4010, a decline of 278.30% compared to -¥0.1060 in 2021[28] - The weighted average return on net assets for 2022 was -24.99%, a decrease of 19.26 percentage points from -5.73% in 2021[29] Debt and Financial Risks - As of the end of 2022, funds occupied by related parties amounted to ¥567,988,400, which is 20.30% of the company's audited net assets[9] - The company has faced a significant risk due to the failure to clear or rectify the fund occupation within one month, leading to continued risk warning for its stock[9] - The company holds a total debt of ¥313,335,013.80 against a related party currently undergoing bankruptcy liquidation[11] - The company reported a total debt of 313,335,013.80 CNY owed to Yiti Group, classified as unsecured debt[164] - As of the end of 2022, the funds occupied by Zhongzhu Group and other related parties amounted to 56,798.84 CNY, representing 20.30% of the company's audited net assets[166] Shareholder Changes and Governance - The largest shareholder, Langdi Technology, acquired 19.077% of the company's shares, becoming the first major shareholder[13] - A significant change in the company's major shareholders has occurred, leading to potential uncertainties regarding control changes[14] - The company has faced risks related to the potential change in control due to significant shareholder changes[165] - The company has experienced significant changes in its major shareholders, with Langdi Technology becoming the largest shareholder holding 19.077% of the total shares[165] - The company has established a complete independent business system, maintaining operational independence from its controlling shareholder[170] Audit and Compliance - The company received a qualified audit opinion from Dahua Certified Public Accountants for its 2022 financial statements[5] - The company emphasizes transparency in information disclosure, adhering to legal requirements and ensuring all shareholders have equal access to information[174] - The company has committed to rectifying past compliance issues, as indicated by the conclusion of investigations without administrative penalties in 2021[192] - The company faced public reprimands from the Shanghai Stock Exchange for information disclosure violations involving its major shareholders and executives[193] - The company is required to strengthen internal management to prevent future violations of information disclosure regulations[194] Strategic Focus and Future Plans - The company plans to focus on new product development and market expansion strategies in the upcoming fiscal year[27] - The company plans to strengthen its operations in the pharmaceutical, medical, and real estate sectors, focusing on resource integration and strategic adjustments[36] - The company aims to maintain steady growth in its pharmaceutical, medical, and real estate sectors while fulfilling its social responsibilities[73] - The company is exploring market expansion opportunities and potential mergers and acquisitions as part of its growth strategy in response to industry consolidation trends[143] - The company will prioritize asset revitalization and industry structure transformation, enhancing product competitiveness and expanding sales channels across its pharmaceutical and hospital sectors[148] Research and Development - The company continues to focus on innovation in drug development and has received multiple awards for its research projects[72] - The company is advancing the research and development of the SCM-198 project, which is aimed at lowering blood lipids and preventing strokes, with ongoing clinical trials[77] - The company’s subsidiary has completed the Phase II clinical research for Genistein capsules and is progressing to Phase III studies[78] - The company has exclusive rights to 8 patents related to SCM-198, which is aimed at cardiovascular disease prevention and treatment[123] - The company is actively pursuing FDA submissions for SCM-198 as part of its development strategy[123] Market Conditions and Industry Trends - The real estate market in China is experiencing a downturn, with a focus on stabilizing policies to support housing demand and prevent systemic risks in the industry[57] - The government emphasizes that housing is for living, not speculation, and is implementing measures to support rigid and improved housing needs[58] - The healthcare industry is expected to grow significantly, with the government aiming to enhance the medical service system by 2025, improving resource allocation and emergency response capabilities[55] - The pharmaceutical industry in China is expanding rapidly, with a focus on high-quality development and compliance with new regulations[54] - The medical device industry in China is becoming a major emerging market, with domestic innovation accelerating the development and market entry of new products[112] Management and Governance - The company appointed Wang Bo as the new CEO on November 22, 2022, with a term until the completion of the current board's term[181] - The company appointed Huang Guanghui as the Executive Vice President on December 23, 2022, with a term until the completion of the current board's term[182] - The company’s Vice President, Si Peichao, was promoted from Executive Vice President on December 23, 2022[182] - The management team includes individuals with extensive experience in various sectors, enhancing the company's operational capabilities[181] - The company has established a remuneration and assessment committee to determine the compensation of directors and senior management, ensuring alignment with the company's assessment system[187]

2022 年第三季度报告 证券代码：600568 证券简称：ST 中珠 中珠医疗控股股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | | 年初至报告期末 | | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 127,133,102.93 | -25.19 | 379,630,267. ...

Financial Position and Performance - The company reported a net asset of 56,798.84 million yuan occupied by related parties, which is 15.79% of the audited net assets as of the end of 2021[8]. - The company has a total debt claim against Yiti Group amounting to 313,335,013.80 yuan, with no property collateral[10]. - The company’s stock continues to be under risk warning due to the financial issues with related parties[8]. - The company’s operating revenue for the first half of 2022 was RMB 252.50 million, representing a 10.21% increase compared to RMB 229.10 million in the same period last year[24]. - The net profit attributable to shareholders of the listed company improved to a loss of RMB 27.20 million, a 43.43% reduction from a loss of RMB 48.08 million in the previous year[24]. - The net cash flow from operating activities was RMB 10.32 million, a significant turnaround from a negative cash flow of RMB 99.53 million in the same period last year, marking an increase of 110.37%[24]. - The total assets at the end of the reporting period were RMB 4.41 billion, down 1.08% from RMB 4.46 billion at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased slightly by 0.76% to RMB 3.57 billion from RMB 3.60 billion at the end of the previous year[24]. - The basic earnings per share improved to -0.0136 yuan per share, a 43.57% increase compared to -0.0241 yuan per share in the same period last year[25]. - The weighted average return on net assets increased by 0.52 percentage points to -0.7588% from -1.2746% in the previous year[25]. - The company received government subsidies amounting to RMB 13.67 million, which are closely related to its normal business operations[26]. Shareholding and Control - As of the announcement date, Yiti Group holds 12.661% of the company's total shares, which is 252,324,862 shares[11]. - On August 5, 2022, Landi Technology won the auction for Yiti Group's shares in the company for 439,423,747.17 yuan, which represents 12.661% of the total shares[12]. - The total shares held by Yiti Group and its concerted actors amount to 324,156,729 shares, representing 16.266% of the total share capital[78]. - The first extraordinary shareholders' meeting in 2022 had a total of 123,056,061 shares represented, accounting for 41.2126% of the voting shares[83]. - The company has a significant concentration of shareholding, with multiple shareholders holding over 5% of the total shares, indicating potential uncertainty in control changes[80]. - The company has committed to not transferring shares held prior to the issuance for 12 months and shares subscribed in the private placement for 36 months[91]. - The company has ensured that any necessary related party transactions will be conducted at market prices to minimize and avoid related party transactions[92]. Legal and Regulatory Matters - The company has taken legal action to recover compensation from Yiti Group for unfulfilled performance commitments, amounting to 17,423,025 shares[10]. - The company has reported a series of legal disputes affecting its financial position, with ongoing litigation impacting its operational strategy[103]. - The company is actively pursuing recovery of debts through legal channels to safeguard its financial interests[102]. - The company is involved in a civil lawsuit regarding the acquisition of Aide Hospital, with a claim amount of RMB 50 million[104]. - The company has a pending civil lawsuit with Zheshang Bank, claiming RMB 25 million due to management failures related to a contractual commitment[104]. - The company has won a first-instance judgment in a lawsuit against Shen Mimi, with the claim amount being RMB 25,732.25[104]. - The company has reported no significant litigation or arbitration matters during the reporting period[101]. Business Segments and Operations - The pharmaceutical segment focuses on the research, production, and sales of specialized ophthalmic drugs, with key products including eye drops and tablets, and ongoing projects like SCM-198 for lipid-lowering and stroke prevention[30]. - In the medical sector, the company operates tumor treatment products, with 13 collaborative tumor radiotherapy centers, of which 5 are currently operational[31]. - The real estate segment is primarily engaged in residential property development in Zhuhai, with 4 projects currently for sale, including the Shanhai Jian Phase II project[32]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[24]. - The company has a strategic goal of developing a full industry chain in anti-tumor services, enhancing its operational management capabilities[33]. - The company is committed to innovation in drug development, combining in-house research with external partnerships[30]. Financial Management and Strategy - The company emphasized cost management, implementing budget management to control expenditures effectively[47]. - Continuous investment in new drug research and development and core technology for medical devices was maintained to enhance market competitiveness[48]. - The company plans to continue improving its financial performance and operational efficiency in the upcoming quarters[24]. - The company completed the liquidation of two entities to reduce investment risks and improve operational efficiency[46]. - The company focused on optimizing its asset structure and established two new subsidiaries in real estate and property management[46]. Market and Economic Environment - The healthcare industry is characterized by strong demand resilience, with ongoing reforms expected to expand the overall market capacity[38]. - The real estate sector is experiencing a shift from deleveraging to stabilizing leverage, with government support aimed at restoring market confidence and normalizing transactions[37]. - The pharmaceutical industry faced significant operational impacts due to the pandemic, but production gradually resumed as the situation improved[36]. - The Ministry of Industry and Information Technology and other departments issued the "14th Five-Year Plan for Pharmaceutical Industry Development," emphasizing innovation in product development and improving industrial technology levels[36]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 30, 2022, ensuring compliance with regulatory requirements[169]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial reports accurately reflect its financial position and performance[175]. - The company has not reported any changes in the accounting policies or prior period error corrections during the current period[158]. - The company has not disclosed any significant related party transactions during the reporting period[109]. - The company has not engaged in any major asset acquisitions or sales during the reporting period[110].

Financial Performance - The company's operating revenue for Q1 2022 was ¥122,493,820.06, representing a year-on-year increase of 31.17%[5] - The net profit attributable to shareholders was a loss of ¥4,107,942.56, an increase in loss of 83.41% compared to the same period last year[5] - Basic earnings per share were -¥0.0021, with a year-on-year increase in loss of 83.06%[6] - Total operating revenue for Q1 2022 was CNY 122,493,820.06, an increase of 31.2% compared to CNY 93,388,534.23 in Q1 2021[20] - Total operating costs for Q1 2022 were CNY 126,995,078.54, up 10.9% from CNY 114,527,575.61 in Q1 2021[20] - Net profit for Q1 2022 was CNY 1,621,721.13, a significant recovery from a net loss of CNY 26,438,456.07 in Q1 2021[21] - The company reported a comprehensive income total of CNY 1,622,794.27 for Q1 2022, compared to a comprehensive loss of CNY 26,545,729.18 in Q1 2021[22] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.0021, improving from CNY -0.0124 in Q1 2021[22] Cash Flow - The net cash flow from operating activities was a negative ¥32,622,357.77, reflecting a significant decline of 6,011.91%[5] - Cash flow from operating activities showed a net outflow of CNY -32,622,357.77 in Q1 2022, compared to a smaller outflow of CNY -533,750.57 in Q1 2021[25] - Cash inflow from investment activities was CNY 102,763,906.22 in Q1 2022, a decrease from CNY 122,444.09 in Q1 2021[25] - The company recorded a net cash inflow from investment activities of CNY 89,680,865.10 in Q1 2022, contrasting with a net outflow of CNY -123,595,874.39 in Q1 2021[25] - The net cash flow from financing activities was -$21,721,780.07, a decrease of $1,355,953.02 compared to the previous period[26] - The total cash and cash equivalents at the end of the period amounted to $562,683,660.16, showing a decrease from $694,509,394.33 at the beginning of the period[26] - The net increase in cash and cash equivalents was $35,336,727.26, compared to a decrease of $125,485,577.98 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,402,604,124.20, a decrease of 1.24% from the end of the previous year[6] - As of March 31, 2022, the total assets amounted to RMB 4,402,604,124.20, a decrease from RMB 4,457,864,645.56 at the end of 2021, reflecting a decline of approximately 1.24%[18] - Total current liabilities decreased to RMB 349,276,322.56 from RMB 402,659,497.81, showing a reduction of around 13.3%[19] - The total liabilities decreased to RMB 672,353,538.43 from RMB 729,236,854.06, reflecting a decline of about 7.8%[19] - The company's inventory stood at RMB 636,797,918.70, slightly down from RMB 641,676,842.66, indicating a decrease of approximately 0.77%[18] - The total equity attributable to shareholders was RMB 3,593,336,128.96, a slight decrease from RMB 3,597,442,998.38, representing a decline of about 0.11%[19] - The company reported a net loss of RMB 1,505,935,246.61 in retained earnings, worsening from a loss of RMB 1,501,827,304.05[19] - The long-term investments remained stable at RMB 608,370,985.34, with a minor decrease from RMB 609,512,710.44[18] Research and Development - The company's research and development expenses decreased by 55.66% due to reduced investment in the pharmaceutical sector[11] - Research and development expenses decreased to CNY 3,727,371.97 in Q1 2022 from CNY 8,405,433.57 in Q1 2021, indicating a strategic shift in R&D investment[20] Other Notable Points - The company received a significant tax refund, resulting in a 100% increase in cash received from tax refunds[11] - The company reported a 46.45% increase in accounts receivable due to new medical insurance settlement receivables[10] - The company’s short-term borrowings increased by 50.10% due to new credit borrowings from subsidiaries[10] - The company’s cash received from the disposal of fixed assets increased by 303.09% compared to the previous period[11] - The company has not disclosed any significant new product developments or market expansion strategies during this reporting period[16]

Financial Performance - The company reported a net profit attributable to the parent company of -211,282,839.49 CNY for the year 2021, with a parent company net profit of -18,529,013.57 CNY[6]. - The undistributed profits at the beginning of the year were -1,295,458,127.27 CNY, and by the end of 2021, they decreased to -1,313,987,140.84 CNY[6]. - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves for the year 2021 due to the negative profit situation[6]. - The company’s auditor issued a qualified opinion on the financial statements for the year 2021, highlighting significant concerns regarding the financial health of the company[5]. - The company's operating revenue for 2021 was RMB 581,059,366.14, a decrease of 20.13% compared to RMB 727,473,784.95 in 2020[28]. - The net profit attributable to shareholders of the listed company was a loss of RMB 211,282,839.49, compared to a profit of RMB 3,218,860.73 in 2020, representing a significant decline[28]. - The net cash flow from operating activities decreased by 62.10% to RMB 94,043,010.46 from RMB 248,153,577.88 in the previous year[28]. - The total assets at the end of 2021 were RMB 4,457,864,645.56, down 1.49% from RMB 4,525,334,908.56 at the end of 2020[28]. - The basic earnings per share for 2021 was -0.1060, a decrease of 6,725.00% compared to 0.0016 in 2020[29]. - The weighted average return on net assets was -5.73% in 2021, down 5.82 percentage points from 0.09% in 2020[30]. - The net assets attributable to shareholders of the listed company decreased by 5.23% to RMB 3,597,442,998.38 at the end of 2021 from RMB 3,796,107,155.95 at the end of 2020[28]. - The company reported a net profit of -215,177,669.42 attributable to shareholders after deducting non-recurring gains and losses, compared to -58,623,115.42 in 2020, indicating a decline of 267.05%[28]. Shareholder and Debt Issues - As of the end of 2021, the funds occupied by the controlling shareholder and its related parties amounted to 56,798.84 million CNY, which is 15.79% of the company's audited net assets[11]. - The company has filed a debt claim of 28,267.93 million CNY against the bankrupt Shenzhen Yiti Group, which is currently undergoing liquidation[13]. - The company’s stock continues to be subject to risk warnings due to the financial issues and the failure to rectify the fund occupation situation within the stipulated time[11]. - The company’s major shareholders include Shenzhen Yiti Group, which holds 12.661% of the total shares, currently in bankruptcy proceedings[14]. - The company is at risk of changes in controlling shareholders, with significant stakes held by various entities, including 12.661% by Yiti Group, which is in bankruptcy proceedings[160]. Market and Operational Strategy - The company has no plans for market expansion or new product launches as it focuses on stabilizing its current operations[6]. - The company has not reported any new strategies or technological developments in the recent financial disclosures[6]. - The company plans to focus on expanding its market presence and developing new products and technologies in the upcoming fiscal year[1]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the healthcare sector[1]. - The overall revenue growth trajectory from Q1 to Q4 indicates a positive trend, but the persistent net losses highlight the need for strategic adjustments moving forward[32]. - The company plans to continue leveraging new technologies and market opportunities in the healthcare sector to drive future growth[38]. Industry Trends and Regulatory Environment - The pharmaceutical industry experienced significant policy reforms in 2021, with a focus on price reductions and the promotion of generic drugs, which could impact the company's future strategies[40]. - The national medical insurance drug catalog now includes a total of 2,860 drugs, with the approval time for innovative drugs to be included in the insurance gradually shortening[41]. - The introduction of the patent term compensation system allows original drug companies to have a longer market exclusivity period, enhancing profit potential and encouraging R&D[42]. - The new drug registration approval process has been standardized, with specific guidelines issued for various drug types, improving the regulatory framework for drug approvals[43]. - The establishment of a multi-tiered national medical security system aims to enhance the accessibility and affordability of healthcare services[44]. - The implementation of clinical value-oriented drug development guidelines is expected to influence the R&D direction of innovative drugs significantly[44]. - The reform of medical service pricing is being piloted, with a goal to promote a sustainable and efficient healthcare pricing system by 2025[46]. - The new medical insurance directory encourages innovation and accelerates the market entry of insured drugs through price negotiations and dynamic adjustments[46]. Research and Development - The company is committed to enhancing its core competitiveness through continuous R&D in medical devices and pharmaceuticals[73]. - The company is advancing the clinical research of its drug SCM-198, with Phase II clinical trials currently in preparation[72]. - The company is developing Genistein capsules, a Class 1 new drug in traditional Chinese medicine, aimed at preventing and treating postmenopausal osteoporosis, currently in the preparation stage for Phase III clinical trials[130]. - The company reported a research and development (R&D) investment of 22.48% of its operating income, significantly higher than the industry average of 40,277.79 million RMB[135]. - The R&D investment for the SCM-198 project was 777.13 million RMB, representing 12.55% of operating income, with a year-on-year increase of 78.40%[135]. Governance and Compliance - The company emphasizes information disclosure and has designated a secretary to ensure compliance with relevant laws and regulations[170]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[169]. - The company actively engages with stakeholders to enhance investor relations and maintain transparency in the capital market[172]. - The company’s governance practices comply with relevant laws and regulations, ensuring the protection of investor interests[172]. - The company has implemented measures to strengthen internal controls and governance to protect the interests of all shareholders, especially minority shareholders[166]. Challenges and Risks - The company faces significant operational challenges due to the ongoing COVID-19 pandemic and economic uncertainties, impacting funding and resource allocation for multiple medical projects[157]. - The company faces risks related to industry policy changes, which could impact operations and market positioning[155]. - The company is navigating a challenging regulatory environment with ongoing healthcare reforms aimed at improving the quality of medical services and promoting innovation in the pharmaceutical sector[146].

Financial Performance - The company's operating revenue for Q3 2021 was CNY 169,944,959.97, representing a decrease of 4.42% compared to the same period last year[5] - The net profit attributable to shareholders was CNY -15,417,086.30, a decline of 4.97% year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY -17,215,945.82, down 5.02% from the previous year[5] - The company reported a year-to-date decrease of 37.85% in net profit attributable to shareholders compared to the previous year[10] - The net loss for the first three quarters of 2021 was CNY 63,931,589.97, compared to a net loss of CNY 1,290,544,464.56 in the same period of 2020[23] - The net profit for Q3 2021 was -60,648,223.35 RMB, compared to -37,342,516.67 RMB in Q3 2020, representing an increase in net loss of approximately 62.2% year-over-year[24] - Operating profit for Q3 2021 was -41,856,897.97 RMB, worsening from -15,611,845.61 RMB in the same period last year[24] - Basic and diluted earnings per share for Q3 2021 were both -0.0319 RMB, compared to -0.0231 RMB in Q3 2020[24] Cash Flow and Assets - The cash flow from operating activities for the year-to-date was CNY 63,489,360.67, showing a significant decrease of 64.32% compared to the same period last year[6] - Cash flow from operating activities for the first three quarters of 2021 was 63,489,360.67 RMB, down 64.3% from 177,953,434.13 RMB in the first three quarters of 2020[25] - The company's cash flow from operating activities showed a significant improvement, with a net cash inflow of CNY 20,473,271.14 compared to a cash outflow in the previous year[23] - Total cash and cash equivalents at the end of Q3 2021 were 578,267,687.32 RMB, a decrease from 595,280,662.93 RMB at the end of Q3 2020[26] - Cash and cash equivalents as of September 30, 2021, were CNY 579,870,776.99, a decrease of 17% from CNY 698,609,658.27 at the end of 2020[18] - Total assets at the end of the reporting period were CNY 4,672,341,521.12, an increase of 3.25% from the end of the previous year[6] - Total assets as of September 30, 2021, amounted to CNY 4,672,341,521.12, an increase from CNY 4,525,334,908.56 at the end of 2020[20] - Current assets totaled approximately $2.10 billion, with a slight decrease of $444.65 thousand from the previous period[28] - Non-current assets decreased to approximately $2.43 billion, reflecting an increase in right-of-use assets by $291.37 million[28] Liabilities and Equity - The equity attributable to shareholders at the end of the reporting period was CNY 3,732,340,188.95, a decrease of 1.68% compared to the end of the previous year[6] - Total liabilities increased to CNY 755,887,649.82 from CNY 545,442,455.38, indicating a rise of 38.4%[19] - The company’s total liabilities increased, impacting its financial stability and future investment capabilities[27] - Total liabilities reached approximately $545.44 million, a decrease of $290.93 million compared to the previous period[29] - Shareholders' equity totaled approximately $3.98 billion, remaining stable compared to the previous period[30] - The company reported a negative retained earnings of approximately $1.29 billion, indicating accumulated losses[30] Shareholding Structure - Shenzhen Yiti Investment Holding Group Co., Ltd. holds 252,324,862 shares, accounting for 12.66% of the total share capital, and is currently in bankruptcy liquidation[16] - Xiao Feiying holds 164,555,403 shares, representing 8.26% of the total share capital[16] - Shenzhen Landi Technology Development Co., Ltd. owns 127,848,000 shares, which is 6.42% of the total share capital[16] - Guangzhou Yunying Capital Management Co., Ltd. has 122,337,830 shares, making up 6.14% of the total share capital[16] - Zhuhai Zhongzhu Group Co., Ltd. holds 119,757,422 shares, accounting for 6.01% of the total share capital[16] - Huang Pengbin owns 104,118,991 shares, representing 5.22% of the total share capital[16] - The total shareholding of major shareholders (over 5%) is close, indicating potential uncertainty in future control changes[16] - The total shareholding of Yiti Group and its concerted actors is 16.47% of the total share capital[16] Regulatory and Audit Information - The company did not conduct an audit for the Q3 financial statements[4] - The company received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations, which has since been resolved without penalties[15] - The company completed a judicial auction where Zeng Yamei acquired 56,926,989 shares, representing 2.86% of the total share capital[15] Cost Management - Total operating costs for the first three quarters of 2021 were CNY 431,200,140.63, down from CNY 524,772,566.40 in 2020, reflecting a reduction of 17.8%[23] - The company reported a decrease in management expenses to CNY 105,856,540.80 from CNY 111,338,534.23, reflecting a cost-saving strategy[23] - The company incurred a total of 941,021.74 RMB in non-operating expenses in Q3 2021, significantly higher than 5,039,381.41 RMB in Q3 2020[24] Sector Performance - The decline in net profit was primarily due to a significant reduction in revenue from the real estate sector[10] - Total operating revenue for the first three quarters of 2021 was CNY 399,047,188.66, a decrease of 19.93% compared to CNY 498,228,589.26 in the same period of 2020[23] - The company received cash inflows from investment activities totaling 193,445,411.38 RMB in the first three quarters of 2021, down from 365,483,563.96 RMB in the same period last year[25] - Investment activities generated a net cash outflow of -135,069,474.89 RMB in the first three quarters of 2021, compared to a net inflow of 79,032,888.84 RMB in the same period last year[26]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥229.1 million, a decrease of 28.50% compared to ¥320.4 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥48.1 million, representing a decline of 53.24% from a loss of ¥31.4 million in the previous year[19]. - The net cash flow from operating activities was negative at approximately ¥99.5 million, a significant decrease of 228.29% compared to a positive cash flow of ¥77.6 million in the same period last year[19]. - Basic earnings per share for the reporting period was -0.0241 CNY, a decrease of 53.50% compared to the same period last year[20]. - Diluted earnings per share also recorded -0.0241 CNY, reflecting the same percentage decrease of 53.50% year-on-year[20]. - The weighted average return on net assets was -1.2746%, down by 0.4198 percentage points from the previous year[20]. - The company reported a significant decrease in accounts receivable, down 65.66% to CNY 1,976,775.23 from CNY 5,755,870.01 last year[80]. - The company reported a net profit of -475.51 million CNY for Zhuhai Zhongzhu Hongqi Investment Co., with total assets of 354.01 million CNY[84]. - The company reported a net loss of ¥1,338,621,692.19, compared to a loss of ¥1,290,544,464.56 in the previous period, indicating a worsening of approximately 3.73%[170]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥4.72 billion, an increase of 4.36% from ¥4.53 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased to approximately ¥3.75 billion, down 1.27% from ¥3.80 billion at the end of the previous year[19]. - The total liabilities rose to ¥790,830,378.96, compared to ¥545,442,455.38, indicating an increase of around 44.93%[170]. - The total current assets amounted to RMB 2,057,062,433.25, a decrease from RMB 2,099,488,356.19 as of December 31, 2020, reflecting a decline of approximately 2%[168]. - Cash and cash equivalents were reported at RMB 513,508,885.79, down from RMB 698,609,658.27, indicating a decrease of about 26.5%[168]. - The total owner's equity at the end of the period is 3,893,147,279.00, a decrease from the previous year's total of 3,773,963,325.44, reflecting a change of approximately 3.18%[200]. Operational Developments - The company is engaged in pharmaceutical R&D, focusing on specialized ophthalmic medications and new drug development projects[26]. - In the medical sector, the company has established partnerships with 13 hospitals for tumor radiotherapy centers, with 5 currently operational[28]. - The real estate segment is primarily focused on residential property development in Zhuhai, with 3 projects currently for sale and 1 under construction[29]. - The company aims to enhance hospital management and operational efficiency in its healthcare facilities[33]. - The company employs a mixed procurement model to ensure efficient resource management and cost control in production[30]. - The medical business has diversified into five cooperative models, including equipment sales and hospital operations, to meet client needs[32]. Research and Development - Continuous investment in R&D for new drugs and core medical device technologies to ensure stable business operations[50]. - The company has a strong focus on innovation in the pharmaceutical sector, with ongoing development of new drugs including SCM-198, which has multiple domestic and international patents and is part of a national key technology project[42]. - Research and development expenses increased by 26.20% to CNY 17,060,613.96 from CNY 13,518,640.25 in the previous year[72]. Legal and Compliance Issues - The company has acknowledged the existence of non-operating fund occupation by controlling shareholders and their related parties[6]. - The report includes a risk statement indicating that future plans and forward-looking statements do not constitute a substantive commitment to investors[5]. - The company has not faced any violations in decision-making procedures regarding external guarantees[6]. - The company is currently undergoing multiple medical institution projects, which require substantial funding and pose operational challenges amid strict regulatory environments[86]. - The company has reported a total outstanding debt of approximately 60,239.49 million CNY due to strategic asset sales and ongoing legal disputes[91]. - The company is involved in significant litigation, including disputes related to equity transfer with a total claim amount of RMB 50 million, which has been reported in interim announcements[124]. Shareholding Structure - The largest shareholder, Mr. Xiao Feiying, holds 164,555,403 shares, representing 8.257% of the total share capital[94]. - The company has a significant concentration of shareholding, with the top five shareholders holding a combined 42.1% of the total share capital[94]. - The company has committed to increasing its shareholding by at least 39,857,394 shares within 12 months[106]. - The company has no current plans to increase or decrease its equity holdings in the listed company[106]. - The company’s governance practices comply with relevant laws and regulations, ensuring the legality of meetings and voting procedures[99]. Market Outlook - The pharmaceutical industry is expected to maintain rapid growth due to stable economic development, rising living standards, and increasing government healthcare investment[35]. - The healthcare market is transitioning towards a "big health" model, with increasing demand for diverse medical services and products driven by enhanced public health awareness[37]. - The company is actively seeking new partners to restart the III phase clinical research for its pharmaceutical projects[61]. Financial Management - The company focused on strengthening operational compliance and risk mitigation, including revising company bylaws and enhancing business process management[49]. - A comprehensive cost management system has been established to control operational costs and improve management efficiency[55]. - The company has implemented strict quality control measures and environmental protection initiatives to ensure product safety and compliance[54].

Financial Performance - Operating revenue decreased by 29.61% to CNY 93,388,534.23 compared to the same period last year[6] - Net profit attributable to shareholders was CNY -24,761,796.46, showing a slight improvement of 0.02% year-on-year[6] - The net profit excluding non-recurring gains and losses was CNY -26,156,995.74, a decrease of 7.34% year-on-year[6] - The company reported a net loss of ¥1,315,306,261.02 in retained earnings, indicating ongoing financial challenges[32] - Total operating revenue for Q1 2021 was ¥93,388,534.23, a decrease of 29.6% compared to ¥132,678,078.74 in Q1 2020[37] - Net loss for Q1 2021 was ¥26,438,456.07, compared to a net loss of ¥23,615,659.34 in Q1 2020, representing an increase in loss of 12.0%[38] - The company’s total profit for Q1 2021 was -¥25,135,146.66, compared to -¥20,766,860.18 in Q1 2020, indicating a worsening of 21.5%[37] Assets and Liabilities - Total assets increased by 5.19% to CNY 4,760,205,084.14 compared to the end of the previous year[6] - Total current assets amounted to CNY 2,099,488,356.19 as of December 31, 2020, with a slight adjustment of -CNY 444,651.30[46] - Non-current assets increased to CNY 2,425,846,552.37 as of January 1, 2021, reflecting an adjustment of +CNY 291,374,278.79 due to the new leasing standards[47] - Total liabilities rose to ¥806,858,360.12, compared to ¥545,442,455.38, indicating an increase of around 47.7%[32] - Current liabilities decreased to ¥435,190,201.84 from ¥459,196,500.72, a reduction of approximately 5.6%[31] - Shareholders' equity totaled ¥3,953,346,724.02, slightly down from ¥3,979,892,453.18, a decrease of about 0.7%[32] Cash Flow - Net cash flow from operating activities was CNY -533,750.57, a decrease of 100.89% compared to the previous year[6] - In Q1 2021, the company's operating cash inflow was CNY 149,053,240.84, a decrease of 34.9% from CNY 229,118,110.98 in Q1 2020[42] - The company reported a total cash and cash equivalents balance of CNY 569,023,816.35 at the end of Q1 2021, down from CNY 694,509,394.33 at the beginning of the quarter[43] - Investment activities resulted in a net cash outflow of -CNY 123,595,874.39, significantly higher than -CNY 34,078,877.67 in Q1 2020[43] - The company’s financing activities generated a net cash outflow of -CNY 1,355,953.02, compared to a net inflow of CNY 54,182,839.54 in the previous year[43] Shareholder Information - The number of shareholders at the end of the reporting period was 34,282[10] - The largest shareholder, Shenzhen Yiti Investment Holding Group Co., Ltd., holds 12.66% of shares, totaling 252,324,862 shares[11] - The second-largest shareholder, Zhuhai Zhongzhu Group Co., Ltd., holds 12.19% of shares, totaling 242,992,811 shares[11] - As of now, the company has recovered approximately ¥10,010 million from a total of ¥19,546.71 million owed by a subsidiary, with about ¥9,502.04 million still outstanding[20] Legal and Regulatory Issues - The company is involved in ongoing litigation regarding outstanding debts totaling ¥47,296.81 million from the sale of various subsidiaries, with efforts to recover these funds through legal channels[18] - The company has been subject to an investigation by the China Securities Regulatory Commission for potential violations of information disclosure laws, which may pose risks to its stock listing status[17] - The company has filed a lawsuit against Yiti Group and its affiliates for unfulfilled performance commitments, with the court ruling in favor of the company[26] - Zhongzhu Medical has submitted a debt claim of 28,267,930 RMB in the bankruptcy proceedings of Yiti Group, with the claim status still pending confirmation[27] Operational Metrics - The company reported a government subsidy of CNY 2,002,128.02 related to normal business operations[8] - The company reported a 30.19% decrease in operating costs to ¥72,472,569.42 in Q1 2021 from ¥103,814,433.57 in Q1 2020, mainly due to reduced costs in the real estate sector[14] - Research and development expenses increased to ¥8,405,433.57 in Q1 2021, up 25.7% from ¥6,685,555.10 in Q1 2020[37] - Other income for Q1 2021 was ¥2,002,128.02, a decrease of 40.0% from ¥3,333,547.22 in Q1 2020[37]